<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01460511</url>
  </required_header>
  <id_info>
    <org_study_id>API-E004-CL-D</org_study_id>
    <nct_id>NCT01460511</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of E004 in Children With Asthma</brief_title>
  <official_title>Phase III Study of Epinephrine Inhalation Aerosol for Evaluation of Efficacy and Safety of E004 in Children With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amphastar Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amphastar Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blinded, placebo-controlled, parallel, 4-week
      study in 60 pediatric patients (4-11 years old) with asthma, comparing E004 with Placebo
      HFA-MDI in pediatric patients who are 4-11 years of age with asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint AUC of FEV1's relative change</measure>
    <time_frame>Visit 1 and Visit 3 at 5, 30, 60, 120, 180, 240, and 360 minutes post-dose</time_frame>
    <description>bronchodilator effect expressed as AUC of FEV1's relative change (from the same day baseline) versus time, defined as AUC of ΔFEV1%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of FEV1 volume changes (AUC of change in FEV1)</measure>
    <time_frame>Visit 1 and Visit 3 at 5, 30, 60, 120, 180, 240, and 360 minutes post-dose</time_frame>
    <description>determination of the change in FEV1 from baseline at visit to to post treatment at Visit 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum of change in FEV1% (Fmax)</measure>
    <time_frame>Visit 1 and Visit 3 at 5, 30, 60, 120, 180, 240, and 360 minutes post-dose</time_frame>
    <description>Evaluation of maximum percent change in FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Curves of change in FEV1, and change in FEV1%, versus time</measure>
    <time_frame>Visit 1 and Visit 3 at 5, 30, 60, 120, 180, 240, and 360 minutes post-dose</time_frame>
    <description>Evaluation of curves of change in FEV1 and percent change in FEV1 over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of bronchodilator effect (to onset), determined the time point (within 60 minutes) where FEV1 first reaches ≥12% above Same-Day Baseline.</measure>
    <time_frame>Study Visits 1and 3 within 60 minutes post dose</time_frame>
    <description>Evaluation of how much time elapses (within 60 minutes), until FEV1 first reaches ≥12% above Same-Day Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to peak FEV1 effect (tmax), defined as the time of Fmax.</measure>
    <time_frame>Study Visits 1 and 3 at 5, 30, 60, 120, 180, 240, and 360 minutes post-dose</time_frame>
    <description>Evaluation of how much time elapses until FEV1 reaches its peak</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of efficacy (duration), defined as the total length of time when ΔFEV1% reaches and stays ≥12% above Same-Day Baseline.</measure>
    <time_frame>Study Weeks 1and 3 at 5, 30, 60, 120, 180, 240, and 360 minutes post-dose</time_frame>
    <description>Evaluation of the total length of time it takes until the change in FEV1% reaches and stays ≥12% above Same-Day Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of positive responders (R%), including all subjects whose Fmax reaches ≥12% above Same-Day Baseline.</measure>
    <time_frame>Study Weeks 1 and 3 within 60 minutes post dose</time_frame>
    <description>Evaluation of what percentage of subjects are positive responders (R%), including all subjects whose Fmaxreaches ≥12% above Same-Day Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean daily morning pre-dose Peak Expiratory Flow Rate (PEF)</measure>
    <time_frame>daily pre-dose</time_frame>
    <description>Evaluation of the mean of daily morning pre-dose Expiratory Flow Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Vital Signs</measure>
    <time_frame>predose, and 3, 20, 60, 360 minutes post-dose</time_frame>
    <description>Monitoring of vital signs (SBP/DBP, and heart rate) at the Screening Visit (Baseline and 30 min post-dose), and at the baseline, 3, 20, 60 and 360 minute time points during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead ECG</measure>
    <time_frame>Pre-dose and , 3, 20 and 60 minutes post-dose (Study Visits 1 and 3)</time_frame>
    <description>Recording of 12-lead ECG (Routine and QT/QTc) at Screening Visit Baseline, and at the baseline, 3, 20 and 60 minute time points during Study Visits 1 and 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albuterol HFA usage for rescue relief of acute asthma symptoms</measure>
    <time_frame>Study Visits 1, 2, and 3, within 30 min predose</time_frame>
    <description>Evaluation Albuterol HFA usage for rescue relief of acute asthma symptoms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>E004 formulation without active ingredient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E004 formulation of epinephrine inhalation aerosol HFA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine Inhalation Aerosol</intervention_name>
    <description>250 mcg (2 inhalations), 4 times daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally healthy male, and premenarchal female, children aged 4 - 11 years upon
             Screening.

          -  With documented asthma, requiring inhaled epinephrine or beta2-agonist treatment, with
             or without concurrent anti-inflammatory therapies for at least 6-months prior to
             Screening.

          -  Being capable of performing spirometry for FEV1

          -  Satisfying criteria of asthma

          -  Can tolerate withholding treatment with inhaled bronchodilators and other allowed
             medications for the minimum washout periods

          -  Demonstrating a Screening Baseline FEV1 that is 50 - 90% of Polgar predicted normal
             value.

          -  Demonstrating an Airway Reversibility,

          -  Demonstrating satisfactory techniques in the use of a metered-dose inhaler (MDIs) and
             a hand held peak expiratory flow meter, after training.

          -  Has been properly consented to participate in this study.

        Exclusion Criteria:

          -  Any current or past medical conditions that, per investigator discretion, might
             significantly affect pharmacodynamic responses to the study drugs

          -  Concurrent clinically significant cardiovascular, hematological, renal, neurologic,
             hepatic, endocrine, psychiatric, or malignant diseases.

          -  Known intolerance or hypersensitivity to any component of the study drugs

          -  Recent infection of the respiratory tract

          -  Use of prohibited medications

          -  Having been on other investigational drug/device studies in the last 30 days prior to
             screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Gao, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Amphastar Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Amphastar Site 5</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphastar Site 8</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphastar Site 4</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphastar Site 2</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphastar Site 1</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphastar Site 7</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphastar Site 3</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphastar Site 6</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pinnas JL, Schachtel BP, Chen TM, Roseberry HR, Thoden WR. Inhaled epinephrine and oral theophylline-ephedrine in the treatment of asthma. J Clin Pharmacol. 1991 Mar;31(3):243-7.</citation>
    <PMID>2019665</PMID>
  </reference>
  <reference>
    <citation>Hendeles L, Marshik PL, Ahrens R, Kifle Y, Shuster J. Response to nonprescription epinephrine inhaler during nocturnal asthma. Ann Allergy Asthma Immunol. 2005 Dec;95(6):530-4.</citation>
    <PMID>16400891</PMID>
  </reference>
  <reference>
    <citation>Warren JB, Doble N, Dalton N, Ewan PW. Systemic absorption of inhaled epinephrine. Clin Pharmacol Ther. 1986 Dec;40(6):673-8.</citation>
    <PMID>3780129</PMID>
  </reference>
  <reference>
    <citation>Cripps A, Riebe M, Schulze M, Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med. 2000 Jun;94 Suppl B:S3-9.</citation>
    <PMID>10919679</PMID>
  </reference>
  <reference>
    <citation>Dickinson BD, Altman RD, Deitchman SD, Champion HC. Safety of over-the-counter inhalers for asthma: report of the council on scientific affairs. Chest. 2000 Aug;118(2):522-6.</citation>
    <PMID>10936150</PMID>
  </reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2011</study_first_submitted>
  <study_first_submitted_qc>October 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2011</study_first_posted>
  <last_update_submitted>July 11, 2012</last_update_submitted>
  <last_update_submitted_qc>July 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild bronchial asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

